BAXALTA INCORPORATED

ADNUVIII

PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF BLOOD DISORDERS;

ADVALTIS

Pharmaceutical preparations for the treatment of blood disorders;

ADVANSATE

PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF BLOOD DISORDERS;

ADVATE

PHARMACEUTICAL PRODUCT, NAMELY, ANTIHEMOPHILIC FACTOR USED FOR THE TREATMENT OF HEMOPHILIA;

ADVATE PRO

PHARMACEUTICAL PRODUCTS FOR THE TREATMENT OF BLOOD DISORDERS;PRO;

ADVOLUCIA

PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF HEMOPHILIA;

ADYNOVATE

PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF BLOOD DISORDERS;

AMIGO FACTOR

PLUSH TOY DOLLS AND INTERACTIVE PLAYSETS FOR USE THEREWITH;CLOTHING, NAMELY, A COSTUME WORN DURING A THERAPEUTIC PLAY VISIT WITH CHILDREN SUFFERING FROM IMMUNOLOGICAL DISORDERS;

ARALAST

pharmaceutical preparations, namely, proteinase inhibitors in the nature of Alpha-1 proteinase inhibitors;

BAXALTA

[Education and training services, namely, providing classes, seminars, conferences, lectures and workshops in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care; education services, namely, providing non-downloadable electronic publications in the nature of newsletters and white papers in the field of hemophilia; provision of information for training and teaching relating to pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care; provision of non-downloadable electronic publications, namely, newsletters, articles, brochures and booklets in the field of pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care];[Computer software for use in the inputting of patient information for transmission to health care professionals; computer software for use in calculating and tailoring the optimal dosage for patients; computer application software for recording and analyzing patient information; computer application software, namely, software for tracking and managing patients' medication and wellness; computer software for tracking and managing pharmaceutical infusions and physical conditions of patients with bleeding disorders; computer software program for mobile phones, tablets, hand held devices and computers for tracking patient information and providing educational information in the field of hemophilia treatment options, designed for patients and health care professionals; downloadable electronic publications, namely, newsletters, articles, brochures, booklets, white papers and presentations in the field of pharmaceuticals, health care, health insurance, medical information, bleeding conditions, hemophilia, hematology, immunology, oncology and patient care];Pharmaceutical preparations, substances and products for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceuticals for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceutical preparations, namely, proteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, all containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteral, intramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparations, namely, chemotherapeutic agents;[Printed publications for teaching, namely, brochures, booklets, training manuals and teaching materials, newsletters and white papers in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding conditions, hemophilia, hematology, immunology, oncology and patient care; printed publications, namely, brochures, booklets, training manuals and teaching materials, newsletters and white papers in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding conditions, hemophilia, hematology, immunology, oncology and patient care; publications, namely, printed instructional and educational guides featuring information about bleeding conditions];[Provision of access to computer databases containing medical information related to hematological, immunological and oncological diseases, disorders and treatment];[Medical services and health care; health care services, namely, providing care for human health; medical services, namely, human blood component collection services; medical services, namely, blood purification; medical services, namely, providing medical information in the field of oncology, immunology and hematology via a website; providing an online database for identifying the optimal dosage of medications for patients; medical services, namely, providing free trial prescription service programs for pharmaceutical preparations for the treatment of blood disorders];Medical devices, namely, devices for reconstituting dried pharmaceuticals; medical apparatus and instruments, namely, medical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations;

BAXALTA

Education and training services, namely, providing classes, seminars, conferences, lectures and workshops in the fields of pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care; education services, namely, providing printed publications in the nature of newsletters and white papers in the field of hemophilia; provision of information for training and teaching relating to pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care; provision of non-downloadable electronic publications, namely, newsletters, articles, brochures and booklets in the field of pharmaceuticals, health care, health insurance, medical information, bleeding disorders or conditions, hemophilia, hematology, immunology, oncology and patient care;The mark consists of the word BAXALTA with light rays emanating from the center of the letter X.;Pharmaceutical preparations, substances and products for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceuticals for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceutical preparations, namely, proteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, all containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteral, intramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparations, namely, chemotherapeutic agents;Color is not claimed as a feature of the mark.;Medical devices, namely, devices for reconstituting dried pharmaceuticals; medical apparatus and instruments, namely, medical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations;

BAXJECT

Medical device for reconstituting dried pharmaceuticals;

BAXJECT III

Reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases;

BEAT BLEEDS

Computer application software for healthcare, namely, software for recording and analyzing patient information; computer application software, namely, software for tracking and managing pharmaceutical infusions and physical conditions of patients with bleeding disorders;

BEAT BLEEDS

PRINTED EDUCATIONAL MATERIALS FOR HEALTHCARE PROFESSIONALS AND PATIENTS IN THE FIELD OF HEMATOLOGY BLEEDING DISORDERS;BLEEDS;

BEBULIN

PHARMACEUTICAL PRODUCTS, NAMELY COAGULATION FACTOR CONCENTRATE FOR PROPHYLAXIS AND THE TREATMENT OF PATIENTS WITH BLEEDING DISORDERS;

BIOLIFE

Medical services, namely, blood component collection services;

BIOLIFE CELLULAR THERAPY SERVICES

BIO LIFE CELLULAR THERAPY SERVICES;Medical services, namely, cellular starter material collection services featuring human blood-derived biological raw materials that are eventually processed for biopharmaceutical uses and disease treatments;CELLULAR THERAPY SERVICES;

BIOLIFE CELLULAR THERAPY SERVICES

The mark consists of the term BioLife shown over the words CELLULAR THERAPY SERVICES in all caps, featuring an interlocking circle design in the top right corner.;Color is not claimed as a feature of the mark.;Medical services, namely, cellular starter material collection services;